This trial is testing a new combination therapy of 8-chloroadenosine and venetoclax to see if it is safe and effective in treating patients with acute myeloid leukemia.
- Refractory Acute Myelogenous Leukemia
- Acute Myeloid Leukemia
- Acute Recurrent Myeloid Leukemia
2 Primary · 4 Secondary · Reporting Duration: Up to 1 year
1 Treatment Group
Treatment (8-chloroadenosine, venetoclax)
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: 8-Chloroadenosine · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 16 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is 8-Chloroadenosine a safe and reliable treatment for individuals?
"The data available for 8-Chloroadenosine's safety and efficacy is limited, thus it was rated a 1 on the Power team scale." - Anonymous Online Contributor
How many participants have enrolled in the research project thus far?
"Affirmative. Clinicaltrials.gov attests that this research study, which was initially posted on July 25th 2022, is currently recruiting participants. Approximately 30 patients are being called for at a single medical centre." - Anonymous Online Contributor
What are the primary goals of this research endeavor?
"This clinical trial will be evaluated over the course of a 28-day cycle. The primary outcome is to measure adverse effects, while secondary objectives include assessing time to response (defined by ELN criteria 2017) using Kaplan and Meier's product-limit method, determining duration of response according to ELN guidelines and employing Kaplan and Meier once again, as well as measuring overall survival with the same methodology." - Anonymous Online Contributor
Are there any vacancies available in this study for participants?
"Affirmative. The information provided on clinicaltrials.gov suggests that this medical trial is actively enrolling participants and was initially posted on July 25th 2022, with its most recent update occurring on August 15th 2022. At present, the study requires 30 individuals to register from a single facility." - Anonymous Online Contributor